Overview

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of multiple, once-daily, intravenous doses of trans sodium crocetinate (TSC). The effectiveness of TSC in alleviating the symptoms of intermittent claudication (IC) will also be assessed.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Diffusion Pharmaceuticals Inc
Diffusion Pharmaceuticals LLC

Treatments:

Trans-sodium crocetinate
Vitamin A